Bomb Report – Lifestyle
Author:
VANDA PHARMACEUTICALS INC
Vanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence
April 28, 2026
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
April 22, 2026
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
April 9, 2026
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
April 8, 2026
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
March 6, 2026
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
March 6, 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
March 5, 2026